Carnosinol (ZM-1)

Carnosinol, also designated FL-926-16, is a synthetic amino alcohol derivative of the endogenous histidyl dipeptide L-carnosine (beta-alanyl-L-histidine) in which the C-terminal carboxyl group has been reduced to a primary hydroxyl, yielding (2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanol. The modification was rationally designed at the University of Milan by computational modeling of the carnosinase-1 (CNDP1) binding pocket and confers near-complete resistance to enzymatic hydrolysis by human serum carnosinase while preserving active transport through the intestinal H+/peptide cotransporter hPepT1 and maintaining the imidazole-mediated nucleophilic reactivity that underlies carbonyl scavenging [1, 2]. The compound represents the lead candidate in a program of carnosine peptidomimetics developed to overcome the principal pharmacokinetic limitation of oral L-carnosine supplementation: rapid degradation by circulating CNDP1, which reduces the plasma half-life of ingested carnosine to approximately 1.2 minutes in humans and effectively prevents systemic therapeutic concentrations from being achieved at tolerable oral doses [3].

The molecular pharmacology of carnosinol centers on selective, covalent sequestration of reactive carbonyl species (RCS), the electrophilic aldehyde and dicarbonyl byproducts of lipid peroxidation and glycolytic overflow that accumulate under conditions of metabolic stress and drive protein carbonylation, advanced glycation end-product (AGE) formation, and inflammatory signaling through the receptor for advanced glycation end products (RAGE) and the NLRP3 inflammasome. Carnosinol reacts with 4-hydroxynonenal (HNE), acrolein (ACR), and methylglyoxal (MGO) through a two-step mechanism involving initial Schiff base (imine) formation at the primary amine followed by intramolecular Michael addition to produce stable, nonreactive macrocyclic and hemiacetal adducts [1]. Critically, the compound does not react with pyridoxal, the aldehyde form of vitamin B6, establishing selectivity for pathological RCS over essential biogenic aldehydes [1]. In comparative in vitro assays, carnosinol demonstrated the greatest potency and selectivity toward alpha,beta-unsaturated aldehydes among all carbonyl scavengers reported at the time of its characterization, exceeding L-carnosine, D-carnosine, aminoguanidine, and pyridoxamine in HNE consumption and equaling or exceeding hydralazine toward MGO without the nonselective aldehyde quenching that limits hydralazine's therapeutic index [1, 4].

Preclinical pharmacology spans three principal disease models. In fructose-fed rats, carnosinol at 10 and 45 mg/kg for three weeks dose-dependently reduced HNE-protein adducts in plasma, liver, and kidney; normalized circulating triglycerides, cholesterol, glucose, insulin, and C-reactive protein; reduced hepatic aminotransferases; and lowered blood pressure to levels comparable to rosiglitazone, with all improvements independent of changes in body weight or energy expenditure [1]. In mice on a high-fat high-sucrose (HFHS) diet, including both wild-type and glutathione peroxidase 4 heterozygous (GPx4+/minus) animals modeling enhanced carbonyl stress, 45 mg/kg for twelve weeks normalized insulin-stimulated glucose uptake in extensor digitorum longus muscle, shifted hepatic steatosis from macrovesicular to microvesicular morphology, blunted fibrosis by picrosirius red staining and hydroxyproline content, decreased RAGE expression, and improved oral glucose tolerance in wild-type animals [1]. In db/db mice, a genetic model of type 2 diabetes, FL-926-16 at 30 mg/kg prevented the onset of diabetic nephropathy when administered from weeks 6 to 20 (creatinine reduced 80 percent, albuminuria 77 percent, proteinuria 75 percent, glomerular area 34 percent, mesangial expansion 40 to 42 percent) and completely blocked disease progression in a regression protocol from weeks 20 to 34, with reductions in glomerular matrix protein expression, tissue oxidative and carbonyl stress markers, and NLRP3 inflammasome activation [5]. In vitro, carnosinol preserved mitochondrial function in hydrogen-peroxide-challenged L6 skeletal myoblasts more effectively than carnosine or anserine, maintaining PGC-1alpha and sirtuin 3 (SIRT3) expression and upregulating superoxide dismutase 2 (SOD2) and catalase in a concentration-dependent manner [6].

No human clinical trials of carnosinol or FL-926-16 have been completed or reported as of the most recent monograph revision. The compound has a favorable ADMET profile: no inhibition of major cytochrome P450 isoenzymes, no hERG potassium channel interaction, no cytotoxicity up to 100 micromolar in human hepatoma cells, and moderately good oral bioavailability in rats [1]. Carnosinol is manufactured by Flamma S.p.A. and is covered by patents EP 2519507B1 and US 8623900B2. The compound is available as a research-grade material for investigational use. This monograph reviews the chemistry, synthesis, and structural rationale of carnosinol; the selective RCS-scavenging mechanism in molecular detail; the pharmacokinetic and ADMET profile; the preclinical evidence base across metabolic, renal, hepatic, and skeletal muscle models; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five carbonyl-scavenging and carnosine-derivative candidates against carnosinol on five competency standards.